JTE-162 / Japan Tobacco - LARVOL DELTA

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) (clinicaltrials.gov) - P1 | N=5 | Recruiting | Sponsor: Akros Pharma Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2026 ➔ Dec 2026

Enrollment open • Trial completion date • Inflammation • NLRP3

Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) (clinicaltrials.gov) - P1 | N=5 | Not yet recruiting | Sponsor: Akros Pharma Inc.

New P1 trial • Inflammation